{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:48:40Z","timestamp":1794088120262,"version":"4.8.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec id=\"ab-doi240066-4\"><jats:title>Importance<\/jats:title><jats:p>Isotretinoin is the only medical acne treatment capable of inducing acne remission; however, some patients experience acne relapse and require retrials of isotretinoin. There is a need to understand who is most at risk and how daily dose and cumulative dosage can influence outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240066-5\"><jats:title>Objective<\/jats:title><jats:p>To assess rates of acne relapse and isotretinoin retrial and to identify associated factors among patients with acne who received an isotretinoin treatment course.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240066-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cohort study used data from the MarketScan commercial claims database from January 1, 2017, to December 31, 2020, to identify patients with acne who were 12 years or older and had received isotretinoin for 4 months or longer, with at least 1 year of continuous enrollment after completion of isotretinoin. Data analyses were performed from June 30, 2024, to August 1, 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240066-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Multivariable Cox proportional hazards regression was used to quantify associations of patient demographic and treatment characteristics with acne relapse and isotretinoin retrial.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240066-8\"><jats:title>Results<\/jats:title><jats:p>A total of 19\u202f907 patients (mean [SD] age, 20.6 [7.8] years; 10\u202f504 females [52.8%]) were included, among whom 4482 (22.5%) had acne relapse and 1639 (8.2%) had isotretinoin retrial. Female sex (hazard ratio [HR], 1.43; 95% CI, 1.35-1.52) was significantly associated with increased rates of acne relapse, and isotretinoin cumulative dosage (mg\/kg) was associated with a decreased rate of acne relapse (HR, 0.996; 95% CI, 0.995-0.997). Furthermore, daily dose was not associated with decreased risk of acne relapse or isotretinoin retrial among those with conventional and high cumulative dosages. Female sex (HR, 0.68; 95% CI, 0.62-0.76) and isotretinoin cumulative dosage (HR, 0.99; 95% CI, 0.98-0.99) were associated with decreased rates of isotretinoin retrial. Stratification by cumulative dosage indicated that higher cumulative dosage was associated with decreased rates of retrial among patients with low (&amp;amp;lt;120 mg\/kg) and conventional (120-220 mg\/kg), but not high (&amp;amp;gt;220 mg\/kg) cumulative dosage. Maximum daily dose (mg\/kg\/d) was not negatively associated with acne relapse or isotretinoin retrial in patients with cumulative dosage of 120 mg\/kg or more.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240066-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings of this cohort study suggest that higher cumulative dosage may potentially reduce risk of acne relapse and isotretinoin retrial. Furthermore, daily dose was not associated with decreased risk of the outcomes for conventional and high cumulative dosage; therefore, daily dosing could be individualized to patient goals and preferences.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.5416","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T16:00:43Z","timestamp":1736956843000},"page":"367","source":"Crossref","is-referenced-by-count":22,"title":["Acne Relapse and Isotretinoin Retrial in Patients With Acne"],"prefix":"10.1001","volume":"161","author":[{"given":"Jenny","family":"Lai","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Associate Editor and Evidence-based Practice Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"doi240066r1","doi-asserted-by":"publisher","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris.","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi240066r2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1440-0960.2010.00657.x","article-title":"Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin.","volume":"51","author":"Rademaker","year":"2010","journal-title":"Australas J Dermatol"},{"issue":"1","key":"doi240066r3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2133.1984.tb04030.x","article-title":"Remission rates in acne patients treated with various doses of 13-cis-retinoic acid (isotretinoin).","volume":"111","author":"Jones","year":"1984","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240066r4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2133.1993.tb11850.x","article-title":"Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?","volume":"129","author":"Stainforth","year":"1993","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240066r5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2133.1993.tb11849.x","article-title":"Isotretinoin for acne vulgaris\u201310 years later: a safe and successful treatment.","volume":"129","author":"Layton","year":"1993","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240066r6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/archderm.134.3.376","article-title":"Recurrence rates after the first course of isotretinoin.","volume":"134","author":"White","year":"1998","journal-title":"Arch Dermatol"},{"issue":"3","key":"doi240066r7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000018130","article-title":"Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients.","volume":"198","author":"Lehucher-Ceyrac","year":"1999","journal-title":"Dermatology"},{"issue":"3","key":"doi240066r8","first-page":"369","article-title":"Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait.","volume":"4","author":"Al-Mutairi","year":"2005","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"doi240066r9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000090658","article-title":"Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin.","volume":"212","author":"Qu\u00e9reux","year":"2006","journal-title":"Dermatology"},{"issue":"6","key":"doi240066r10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/j.1365-2133.2007.08250.x","article-title":"Isotretinoin therapy and the incidence of acne relapse: a nested case-control study.","volume":"157","author":"Azoulay","year":"2007","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi240066r11","first-page":"963","article-title":"Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients.","volume":"7","author":"Liu","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi240066r12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000249320","article-title":"The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study.","volume":"172","author":"Harms","year":"1986","journal-title":"Dermatologica"},{"issue":"9","key":"doi240066r13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/j.1468-3083.2010.03933.x","article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission.","volume":"25","author":"Borghi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi240066r14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jaad.2010.06.025","article-title":"Could higher doses of isotretinoin reduce the frequency of treatment failure in patients with acne?","volume":"65","author":"Coloe","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi240066r15","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jamadermatol.2013.6746","article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.","volume":"149","author":"Blasiak","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi240066r16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ad.2012.05.004","article-title":"Acne relapse rate and predictors of relapse following treatment with oral isotretinoin.","volume":"104","author":"Morales-Cardona","year":"2013","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"doi240066r17","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaad.2019.06.1293","article-title":"Retrospective case series of isotretinoin outcomes for acne in 393 female patients at Baylor College of Medicine during 2012-2016.","volume":"82","author":"Fernandez","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi240066r18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15109","article-title":"Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris.","volume":"34","author":"Demirci Saadet","year":"2021","journal-title":"Dermatol Ther"},{"key":"doi240066r19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.733526","article-title":"Advantages of tailored isotretinoin treatment in moderate to severe acne: real-life data.","volume":"12","author":"Skroza","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"doi240066r20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1055\/s-0038-1673354","article-title":"Truven Health Analytics MarketScan databases for clinical research in colon and rectal surgery.","volume":"32","author":"Kulaylat","year":"2019","journal-title":"Clin Colon Rectal Surg"},{"issue":"5","key":"doi240066r21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.jaad.2020.04.145","article-title":"Big data in dermatology: publicly available health care databases for population health research.","volume":"83","author":"Tripathi","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi240066r22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jamadermatol.2023.2363","article-title":"Temporal trends in the use of systemic medications for acne from 2017 to 2020.","volume":"159","author":"Barbieri","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"36","key":"doi240066r23","first-page":"1","article-title":"Anthropometric reference data for children and adults: United States, 2015-2018.","author":"Fryar","year":"2021","journal-title":"Vital Health Stat 3"},{"issue":"3","key":"doi240066r24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/0019-5154.131455","article-title":"Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris.","volume":"59","author":"Rao","year":"2014","journal-title":"Indian J Dermatol"},{"issue":"3","key":"doi240066r25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1440-0960.2012.00947.x","article-title":"Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?","volume":"54","author":"Rademaker","year":"2013","journal-title":"Australas J Dermatol"},{"issue":"3","key":"doi240066r26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/jvc2.154","article-title":"A systematic review of isotretinoin dosing in acne vulgaris.","volume":"2","author":"Daly","year":"2023","journal-title":"JEADV Clin Pract"},{"issue":"6","key":"doi240066r27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/j.1365-2133.2010.10152.x","article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study.","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240066r28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210445","article-title":"Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.","volume":"14","author":"Charrow","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"doi240066r29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2007.06.045","article-title":"The prevalence of acne in adults 20 years and older.","volume":"58","author":"Collier","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi240066r30","first-page":"692","article-title":"[Acne, hyperandrogenism and oral isotretinoin resistance. 23 cases. Therapeutic implications].","volume":"124","author":"Lehucher-Ceyrac","year":"1997","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"doi240066r31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-4632.2012.05691.x","article-title":"Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse.","volume":"52","author":"Cakir","year":"2013","journal-title":"Int J Dermatol"},{"issue":"9","key":"doi240066r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290763","article-title":"Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: a study of the national ambulatory medical care survey from 2002-2016.","volume":"18","author":"Chang","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"doi240066r33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/ijd.12942","article-title":"Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris.","volume":"55","author":"Rademaker","year":"2016","journal-title":"Int J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2829255\/jamadermatology_lai_2025_oi_240066_1744811605.49753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:01:06Z","timestamp":1744815666000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2829255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.5416","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}